People: Transcept Pharmaceuticals Inc (TSPT.W)

Summary

Name	Age	Since	Current Position
G. Kirk Raab	76	2009	Independent Chairman of the Board
Glenn Oclassen	69	2009	President, Chief Executive Officer, Director
Leone Patterson	49	2012	Chief Financial Officer, Vice President
Thomas Soloway	45	2012	Chief Operating Officer, Executive Vice President
Nikhilesh Singh	53	2009	Senior Vice President, Chief Scientific Officer
John Kollins	49	2012	Senior Vice President, Chief Business Officer
Thomas Dietz		2013	Independent Director
Christopher Ehrlich	42	2009	Independent Director
Thomas Kiley	69	2009	Independent Director
Jake Nunn	42	2009	Independent Director
Frederick Ruegsegger	56	2008	Independent Director

» Insider Trading

Biographies

Name	Description
G. Kirk Raab	Mr. G. Kirk Raab serves as an Independent Chairman of the Board of Transcept Pharmaceuticals Inc., since completion of the merger between TPI and Novacea in January 2009. Prior to completion of the merger, Mr. Raab was a member of the TPI board of directors since October 2003, serving as Chairman of the Board since November 2005. From 1985 to 1995, Mr. Raab served variously as President, Chief Operating Officer, Director and Chief Executive Officer of Genentech, Inc., a biotechnology company. From 1981 to 1985, Mr. Raab served as President, Chief Operating Officer and a Director of Abbott Laboratories, a biopharmaceutical company. Since 1995, Mr. Raab has been involved with over 15 public and privately held biotechnology companies, serving as Chairman of the Board of Directors for many of them. Mr. Raab holds a B.A. in political science from Colgate University where he is a Trustee Emeritus.
Glenn Oclassen	Mr. Glenn A. Oclassen serves as President, Chief Executive Officer, Director of Transcept Pharmaceuticals Inc., since completion of the merger between TPI and Novacea in January 2009. rior to completion of the merger, Mr. Oclassen served as the President and Chief Executive Officer of TPI and as a member of the TPI board of directors since July 2003. Prior to co-founding TPI, from 1997 to 1999 he was the President and Chief Executive Officer of NextDerm Inc., a dermatology company founded by Mr. Oclassen that was acquired in 1999 by Procyte Corp. From 1986 to 1992, Mr. Oclassen was the Founder, President and Chief Executive Officer of Oclassen Pharmaceuticals, Inc., a dermatologic drug development and marketing company. He served as Chairman from 1992 to February 1997, at which time the company was acquired by Watson Pharmaceuticals, Inc. Mr. Oclassen holds a B.S. in zoology from San Diego State University.
Leone Patterson	Ms. Leone Patterson has been appointed as Chief Financial Officer, Vice President of Transcept Pharmaceuticals, Inc., with effect from June 25, 2012. Prior to joining Transcept, Ms. Patterson was Vice President and Corporate Controller of NetApp, a data storage company, from November 2010 to June 2012. Ms. Patterson was Vice President of Finance at Exelixis, a biotechnology company, from July 2007 to November 2010. Prior to that, Ms. Patterson served as Vice President of Global Business Planning and Analysis of the Vaccines and Diagnostics Divison of Novartis AG, a pharmaceutical company, from April 2006 to July 2007. From 1999 to 2006, she held several positions, including Vice President, Corporate Controller at Chiron, a biotechnology company. From 1989 to 1999, Ms. Patterson worked in the audit practice of accounting firm KPMG. Ms. Patterson holds a B.S. in business administration and accounting from Chapman University and an Executive M.B.A. from St. Mary’s College.
Thomas Soloway	Mr. Thomas P. Soloway serves as Chief Operating Officer, Executive Vice President of Transcept Pharmaceuticals Inc., since April 4, 2012. Prior to that was Senior Vice President, Operations and Chief Financial Officer since completion of the merger between TPI and Novacea in January 2009. Prior to completion of the merger, Mr. Soloway served as Chief Financial Officer of TPI since July 2003, and as the Senior Vice President, Operations and Chief Financial Officer of TPI since November 2005. Prior to joining TPI, from 1993 to 2002, Mr. Soloway worked with Montreux Equity Partners, a venture capital firm, in the development, structuring and financing of early stage biotechnology companies. Mr. Soloway holds a B.S. in Entrepreneurial Studies from the University of Southern California and an M.B.A. from Georgetown University.
Nikhilesh Singh	Dr. Nikhilesh N. Singh, Ph.D., serves as Senior Vice President, Chief Scientific Officer of Transcept Pharmaceuticals Inc., since of the merger between TPI and Novacea in January 2009. Prior to completion of the merger, Dr. Singh served as Senior Vice President, Chief Scientific Officer of TPI since January 2007, and previously served as Vice President and Chief Scientific Officer of TPI from July 2003 to December 2006 and as a member of the TPI board of directors from July 2003 to November 2005. Prior to co-founding TPI, Dr. Singh served in various roles relating to the development, commercialization and marketing of pharmaceutical products at Procter & Gamble Co., a manufacturer of consumer goods and pharmaceuticals, from August 1987 until June 1995, G. D. Searle & Co., a life sciences company that is currently part of Pfizer Inc., from July 1995 until December 1998, and Watson Pharmaceuticals Inc., a pharmaceuticals manufacturer, from January 1999 until October 2001. Dr. Singh holds a B.S. and M.S. in Pharmacy from the University of Bombay, India, and a Ph.D. in Pharmaceutical Sciences from the University of Alberta, Canada.
John Kollins	Mr. John A. Kollins has been appointed as Senior Vice President, Chief Business Officer of Transcept Pharmaceuticals, Inc., effective June 1, 2012. Prior to joining Transcept, Mr. Kollins was the managing director and founder of Parnassus Advisors, a life sciences advisory firm, from September 2011 to May 2012 and was a managing director and senior advisor at Locust Walk Partners, a life sciences advisory firm, from December 2009 to September 2011. From March 2007 to October 2009, he served successively as Chief Business Officer, Chief Operating Officer, and Chief Executive Officer and director of OXiGENE, a publicly-held biopharmaceutical company. From 2005 to 2007, Mr. Kollins was a consultant to healthcare investment firms and life sciences companies. Mr. Kollins has also served in executive, business development and product management roles at various biopharmaceutical companies, including CovX, Renovis and Elan Pharmaceuticals. Mr. Kollins holds a B.S.E. in mechanical engineering and materials science from Duke University and an M.B.A. from the University of Virginia.
Thomas Dietz	Dr. Thomas J. Dietz, Ph.D., has been appointed as Independent Director of Transcept Pharmaceuticals Inc., effective April 10, 2013. Dr. Dietz has more than 20 years of experience supporting the biopharma industry and the institutional investment community. Prior to his current role as Chairman and CEO of Waypoint Holdings, Dr. Dietz was co-CEO and then CEO and a Director of Pacific Growth Equities, LLC, a San Francisco-based investment bank and institutional brokerage firm from 2004 to 2009, when the firm was acquired by Wedbush Securities. Dr. Dietz served as head of the investment banking division at Webush until November 2010. Prior to becoming CEO at Pacific Growth, Dr. Dietz served as the firm's Director of Equities Research and was an award-winning biotechnology and biopharmaceutical analyst. Dr. Dietz joined Pacific Growth in 1993. Previously, he was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center. Dr. Dietz is a member of several national societies and currently serves as Chairman of Galleon Pharmaceuticals, Inc. and Director of Glialogix, Inc. as well as on the boards of trustees of several non-profit organizations, including the West Bay Region board of the Sutter Health System that includes California Pacific Medical Center, San Francisco. Dr. Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University, St. Louis, and was a National Science Foundation Post-Doctoral Fellow.
Christopher Ehrlich	Mr. Christopher B. Ehrlich serves as an Independent Director of Transcept Pharmaceuticals Inc., since completion of the merger between TPI and Novacea in January 2009. Prior to completion of the merger, Mr. Ehrlich was a member of the TPI board of directors since October 2005. He is currently a Manager Director at InterWest Partners, a venture capital firm, which he joined in August 2000. Prior to joining InterWest, from 1998 to 2000, Mr. Ehrlich was the Director of Licensing and Business Development at Purdue Pharma, a pharmaceutical company. Mr. Ehrlich is also a director of BioMimetic Therapeutics, Inc., a publicly-held biotechnology company. Mr. Ehrlich holds a B.A. in government from Dartmouth College and an M.B.A. from the J.L. Kellogg Graduate School of Management.
Thomas Kiley	Mr. Thomas D. Kiley, Esq., serves as an Independent Director of Transcept Pharmaceuticals Inc., since completion of the merger between TPI and Novacea in January 2009. ior to completion of the merger, Mr. Kiley was a member of the TPI board of directors since January 2004. Since 1988 he has been an attorney, consultant and investor. From 1980 to 1988, he was an officer of Genentech, Inc., a biotechnology company, serving variously as Vice President and General Counsel, Vice President for Legal Affairs and Vice President for Corporate Development. Mr. Kiley is also a director of Geron Corporation, a publicly-held biopharmaceutical company and Ceres, Inc., a publicly-held agricultural biotechnology company. Mr. Kiley holds a B.S. in Chemical Engineering from Pennsylvania State University and a J.D. from George Washington University.
Jake Nunn	Mr. Jake R. Nunn serves as an Independent Director of Transcept Pharmaceuticals Inc., since completion of the merger between TPI and Novacea in January 2009. Mr. Nunn has been a partner at New Enterprise Associates, Inc., a venture capital firm, since June 2006. From January 2001 to June 2006, he was a partner and analyst for the MPM BioEquities Fund, a public life sciences fund at MPM Capital, a venture capital firm. Mr. Nunn holds a B.A. in economics from Dartmouth College and an M.B.A. from the Stanford University Graduate School of Business. Mr. Nunn holds the Chartered Financial Analyst designation and is a member of the CFA Society of San Francisco.
Frederick Ruegsegger	Mr. Frederick J. Ruegsegger serves as an Independent Director of Transcept Pharmaceuticals Inc., since February 2008 and the Transcept Board of Directors since completion of the merger of Novacea and TPI in January 2009. Prior to completion of the merger, Mr. Ruegsegger was a member of the Novacea board of directors since February 2008. Mr. Ruegsegger has been a managing director of Four Oaks Partners, a transaction advisory firm, since April 2012. Mr. Ruegsegger served as chief financial officer of Sterigenics International, Inc., a sterilization technology company, from June 2004 until September 2011. Prior to that, Mr. Ruegsegger served as chief financial officer and chief of staff of Sterigenics’ former parent company, Ion Beam Applications, from May 2002 to June 2004. From October 2000 to May 2002, Mr. Ruegsegger provided financial and general management services, generally as a consultant, to a variety of companies including CentPharm, LLC and Phaethon Communications. Mr. Ruegsegger holds a B.S. in Economics from the University of Illinois and an M.A. in Management from Northwestern University.

Basic Compensation

Name	Fiscal Year Total
G. Kirk Raab	--
Glenn Oclassen	1,854,050
Leone Patterson	--
Thomas Soloway	907,105
Nikhilesh Singh	910,905
John Kollins	--
Thomas Dietz	--
Christopher Ehrlich	--
Thomas Kiley	--
Jake Nunn	--
Frederick Ruegsegger	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
G. Kirk Raab	0	0
Glenn Oclassen	226,095	1,959,220
Leone Patterson	0	0
Thomas Soloway	76,270	497,501
Nikhilesh Singh	0	0
John Kollins	0	0
Thomas Dietz	0	0
Christopher Ehrlich	0	0
Thomas Kiley	0	0
Jake Nunn	0	0
Frederick Ruegsegger	0	0

Insider Trading

Name	Shares Traded	Price
WORTZMAN MARILYN E	4,600	$2.12
WORTZMAN MARILYN E	4,600	$11.40
WORTZMAN MARILYN E	4,600	$10.00
WORTZMAN MARILYN E	4,027	$10.00
WORTZMAN MARILYN E	573	$2.12
WORTZMAN MARILYN E	4,600	$4.14
WORTZMAN MARILYN E	573	$10.00
WORTZMAN MARILYN E	4,027	$1.77
KILEY THOMAS D	3,200	$0.00
SINGH NIKHILESH N	36,709	$7.59
SINGH NIKHILESH N	13,237	$7.59
KENNEDY JOSEPH T	56,666	$8.23
KENNEDY JOSEPH T	56,666	$3.10
KENNEDY JOSEPH T	4,150	$2.68
SOLOWAY THOMAS P	37,520	$0.88
KENNEDY JOSEPH T	4,150	$8.23
SOLOWAY THOMAS P	25,150	$8.23
SOLOWAY THOMAS P	37,520	$8.57
SOLOWAY THOMAS P	25,150	$2.68
KENNEDY JOSEPH T	34,600	$2.68
KENNEDY JOSEPH T	34,600	$7.87
SOLOWAY THOMAS P	13,600	$2.68
SOLOWAY THOMAS P	13,600	$7.87
WORTZMAN MARILYN E	4,000	$8.00
WORTZMAN MARILYN E	4,000	$1.77

» Full list on Insider Trading

People: Transcept Pharmaceuticals Inc (TSPT.W)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: